Response of prostate cancer to addition of dutasteride after progression on abiraterone

Response of prostate cancer to addition of dutasteride after progression on abiraterone

Bibliographic Details
Main Authors:	Jian-Po Lian, Yuan-Yuan Gao, Jing-Jie Tang, Xi Chen, Ying Liu, Deng-Long Wu, Zhen-Fei Li, Sheng-Song Huang
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2021-01-01
Series:	Asian Journal of Andrology
Online Access:	http://www.ajandrology.com/article.asp?issn=1008-682X;year=2021;volume=23;issue=2;spage=222;epage=223;aulast=Lian

Similar Items

Use of dutasteride in carcinoma prostate
by: R P Shrinivas
Published: (2014-01-01)

Update on the use of dutasteride in the management of benign prostatic hypertrophy
by: Joe Miller, et al.
Published: (2007-04-01)

Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate
by: J Miller, et al.
Published: (2009-06-01)

Usage, effectiveness and safety of abiraterone in prostate cancer
by: J. M. Caro Teller, et al.
Published: (2014-03-01)

PSA flare in metastatic castration-resistant prostate cancer patients treated with abiraterone or docetaxel
by: Hui-Ying Liu, et al.
Published: (2016-06-01)

Abiraterone Acetate and Castration Resistant Ductal Adenocarcinoma of the Prostate
by: Edgar Linden-Castro, et al.
Published: (2014-01-01)

Abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Mostaghel EA
Published: (2014-01-01)

Experience with the combination of dutasteride and tamsulosin in the long-term management of benign prostatic hyperplasia
by: Bilal Chughtai, et al.
Published: (2012-10-01)

Fixed-dose combination therapy with dutasteride and tamsulosin in the management of benign prostatic hyperplasia
by: Konstantinos Dimitropoulos, et al.
Published: (2016-02-01)

Abiraterone in the management of castration-resistant prostate cancer prior to chemotherapy
by: Benjamin A. Gartrell, et al.
Published: (2015-08-01)

Influence of hydrophilic additives on the supersaturation and bioavailability of dutasteride-loaded hydroxypropyl- β-cyclodextrin nanostructures
by: Kim MS
Published: (2013-05-01)

Clinical predictor of efficacy of abiraterone acetate in metastatic castraction-resistence prostate cancer progressing after doxcetaxel treatment
by: Chin-Peng Chang, et al.
Published: (2016)

Does dutasteride reduce perioperative blood loss and postoperative complications after transurethral resection of the prostate?
by: R Shanmugasundaram, et al.
Published: (2007-01-01)

Clinical use of abiraterone in the treatment of metastatic castration-resistant prostate cancer
by: Zobniw CM, et al.
Published: (2014-08-01)

Abiraterone acetate: A novel drug for castration-resistant prostate carcinoma
by: R Nandha
Published: (2012-01-01)

Real-world experience with abiraterone in metastatic castration-resistant prostate cancer
by: Yasar Ahmed, et al.
Published: (2017-01-01)

Meta-analysis of the efficacy and safety of combination of tamsulosin plus dutasteride compared with tamsulosin monotherapy in treating benign prostatic hyperplasia
by: Zhongbao Zhou, et al.
Published: (2019-03-01)

The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice.
by: Alexander B Opoku-Acheampong, et al.
Published: (2012-01-01)

The effect of finasteride and dutasteride on the growth of wpe1-na22 prostate cancer xenografts in nude mice
by: Opoku-Acheampong, Alexander Boadu
Published: (2011)

Docetaxel, abiraterone, enzalutamide, apalutamide in patients with metastatic hormone-sensitive prostate cancer
by: Harkirat Singh Talwar
Published: (2021-01-01)

The first experience in using abiraterone acetate in patients with castration-refractory prostate cancer
by: L. M. Rapoport, et al.
Published: (2015-11-01)

Clinical experience with abiraterone acetate application in patients with castration-resistant prostate cancer
by: Ya V Gridneva, et al.
Published: (2014-09-01)

Serious Hypokalemia Associated with Abiraterone Acetate in Patients with Castration-Resistant Prostate Cancer
by: Yutaka Yamamoto, et al.
Published: (2018-01-01)

Design and release kinetics of liposomes containing abiraterone acetate for treatment of prostate cancer
by: Sudipta Das, et al.
Published: (2021-01-01)

Population-Based Study of Docetaxel or Abiraterone Effectiveness and Predictive Markers of Progression Free Survival in Metastatic Castration-Sensitive Prostate Cancer
by: Juan Briones, et al.
Published: (2021-05-01)

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the combination of avodart and tamsulosin trial
by: Andreas Bohle
Published: (2011-04-01)

Effect of a Combination of Dutasteride and Parenteral Testosterone Undecanoate on Testosterone Deficiency Symptoms and Prostate in Patients with Testosterone Efficiency and Benign Prostatic Hyperplasia
by: Min Gu Park, et al.
Published: (2020-06-01)

Abiraterone and MDV3100 inhibits the proliferation and promotes the apoptosis of prostate cancer cells through mitophagy
by: Jingli Han, et al.
Published: (2019-12-01)

Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice.
by: Alexander B Opoku-Acheampong, et al.
Published: (2013-01-01)

Development and formulation for Dutasteride hard capsules dosage form
by: LIU,MING-SIAN, et al.
Published: (2016)

Effect of combination treatment on patient-related outcome measures in benign prostatic hyperplasia: clinical utility of dutasteride and tamsulosin
by: Djavan B, et al.
Published: (2011-03-01)

Review of dutasteride/tamsulosin fixed-dose combination for the treatment of benign prostatic hyperplasia: efficacy, safety, and patient acceptability
by: Barkin J
Published: (2011-10-01)

The REDUCE metagram: a comprehensive prediction tool for determining the utility of dutasteride chemoprevention in men at risk for prostate cancer
by: Carvell eNguyen, et al.
Published: (2012-10-01)

A comparative study of fixed dose of Tamsulosin with finasteride vs Tamsulosin with dutasteride in the management of benign prostatic hyperplasia
by: N K Mohanty, et al.
Published: (2006-01-01)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer
by: Mamta Parikh, et al.
Published: (2021-03-01)

Abiraterone acetate plus LHRH therapy versus abiraterone acetate while sparing LHRH therapy in patients with progressive, metastatic and chemotherapy-naïve, castration-resistant prostate cancer (SPARE): study protocol for a randomized controlled trial
by: Carsten-Henning Ohlmann, et al.
Published: (2017-10-01)

The short-term efficacy and safety of abiraterone acetate with prednisone in metastatic castration-resistant prostate cancer patients in vghtc
by: Chi-Feng Hung, et al.
Published: (2015-06-01)

A Study on the Clinical Outcome of Abiraterone Acetate in Castration Resistant Prostate Cancer Patients
by: Aloysius James, et al.
Published: (2018-01-01)

Abiraterone acetate for early stage metastatic prostate cancer: patient selection and special considerations
by: Castellan P, et al.
Published: (2018-12-01)

Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer
by: Rosenberg JE, et al.
Published: (2012-01-01)